Material Agreements

Blue Star Foods Corp. entered into Agreement with Afritex Ventures, Inc. and Eagle Rising Food Solutions LLC (effective 2024-03-21).

“On April 4, 2024 Blue Star Foods Corp. (the “Company”) entered into a contract manufacturing agreement (the “Agreement”) with Afritex Ventures, Inc., a Texas corporation (the “Supplier), and Eagle Rising Food Solutions LLC, a Florida corporation (the “Buyer”), which was effective March 21, 2024 (the “Effective Date”).”

ADT Inc. amended Sixth Amendment to Receivables Financing Agreement with Mizuho Bank, Ltd., MUFG Bank Ltd., Starbird Funding Corporation, and BNP Paribas valued at $550 million (effective 2024-04-10).

“On April 10, 2024, ADT LLC (“ADT”) and ADT Finance LLC (“ADT Finance”) entered a Sixth Amendment to the Receivables Financing Agreement, among ADT Finance, Mizuho Bank, Ltd., ADT, MUFG Bank Ltd., Starbird Funding Corporation, and BNP Paribas (the “Sixth Amendment to Receivables Financing Agreement”).”

HF Foods Group Inc. amended Amendment with Equiniti Trust Company, LLC (effective 2024-04-11).

“On April 11, 2024, HF Foods Group Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (f/k/a American Stock Transfer & Trust Company, LLC), as rights agent (the “Rights Agent”), entered into an Amendment to the Stockholder Rights Agreement, dated as of April 11, 2024 (the “Amendment”), which amended the Stockholder Rights Agreement, dated as of April 11, 2023 (the “Rights Agreement”), by and between the Company and the Rights Agent.”

Insight Molecular Diagnostics Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $15.8 million (effective 2024-04-11).

“On April 11, 2024, Oncocyte Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of an aggregate of 5,077,387 shares (the “Common Shares”) of common stock of the Company, no par value per share (the “Common Stock”), and pre-funded warrants (“Pre-Funded Warrants”) to purchase up to 342,888 shares of Common Stock, with an exercise price of $0.0001 per share.”

Adaptimmune Therapeutics PLC terminated Strategic Collaboration and License Agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd. (effective 2024-04-10).

“On April 10, 2024, Adaptimmune Limited, a wholly-owned subsidiary of Adaptimmune Therapeutics plc (“Adaptimmune”) received notice of termination of the Strategic Collaboration and License Agreement with Genentech, Inc. (“Genentech”) and F. Hoffman-La Roche Ltd. (the “Agreement”).”

Nurix Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated valued at Issuance and sale of 10,166,667 shares of common stock at $15.00 per share and pre-funded warrants t (effective 2024-04-11).

“On April 11, 2024, Nurix Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated, as the representatives of the several underwriters named in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 10,166,667 shares of its common stock (the “Shares”) and (b) pre-funded warrants to purchase 1,500,100 shares of its common stock (the “Pre-Funded Warrants”) to the Underwriters (the “Offering”).”

LINDBLAD EXPEDITIONS HOLDINGS, INC. entered into Transfer Agreement with Ben Bressler valued at $15,171,664 (effective 2024-04-10).

“On April 10, 2024, Lindblad Expeditions Holdings, Inc., a Delaware corporation (the “Company”), entered into a Transfer Agreement with its subsidiary, Natural Habitat, Inc. (“Natural Habitat”), and Ben Bressler, founder of Natural Habitat, pursuant to which the Company purchased 194 shares of Natural Habitat (the “Shares”) from Mr. Bressler for $15,171,664 (the “Transfer Agreement”).”

Walker & Dunlop, Inc. entered into Fourteenth Amendment to Second Amended and Restated Warehousing Credit and Security Agreement with PNC Bank, National Association valued at extended maturity date to April 11, 2025 (effective 2024-04-11).

“On April 11, 2024, Walker & Dunlop, Inc. (the “ Company ”) and Walker & Dunlop, LLC, the operating subsidiary of the Company (the “ Borrower ”), entered into the Fourteenth Amendment to Second Amended and Restated Warehousing Credit and Security Agreement (the “ Amendment ”) with PNC Bank, National Association, as Lender (“ PNC ”).”

Vivakor, Inc. amended Amended Note with non-affiliated individual lender valued at $1,000,000 (effective 2024-04-08).

“On April 8, 2024, the lender returned an executed amended and restated convertible promissory note for the Loan (the “Amended Note”).”

C-Bond Systems, Inc entered into Promissory Note with 1800 Diagonal Lending LLC valued at $127,963.00 (effective 2024-04-08).

“On April 8, 2024, C-Bond Systems, Inc. (the “Company”) executed a Promissory Note (“Note”) in favor of 1800 Diagonal Lending LLC (the “Investor”) in the aggregate principal amount of $127,963.00 (the “Principal”), and an accompanying Securities Purchase Agreement (“SPA”).”

Ascent Solar Technologies, Inc. amended Amended and Restated Warrant Repurchase Agreements with each of the Investors valued at $3.6 million aggregate repurchase price (effective 2024-04-12).

“On April 12, 2024, the Company entered into Amended and Restated Warrant Repurchase Agreements (the “Amendments”) with each of the Investors.”

TrueCar, Inc. terminated the Lease with Mani Brothers Portofino Plaza (DE), LLC (effective 2024-04-10).

“(the “Company”) entered into an office building lease (the “Lease”) with Mani Brothers Portofino Plaza (DE), LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company leased office space located at 1401 Ocean Avenue, Santa Monica, California (the “Premises”).”

TD SYNNEX CORP entered into Indenture with Citibank, N.A. valued at $600,000,000 aggregate principal amount of 6.100% Senior Notes due 2034 (effective 2024-04-12).

“On April 12, 2024, TD SYNNEX Corporation (“TD SYNNEX” or the “Company”) issued and sold $600,000,000 aggregate principal amount of 6.100% Senior Notes due 2034 (the “Notes,” and such offering, the “Notes Offering”).”

BRANDYWINE OPERATING PARTNERSHIP, L.P. entered into Indenture with The Bank of New York Mellon valued at $400 million (effective 2004-10-22).

“On April 12, 2024, Brandywine Operating Partnership, L.P., a Delaware limited partnership (the “Operating Partnership”), completed its offering and sale (the “Notes Offering”) of $400 million in aggregate principal amount of its 8.875% Guaranteed Notes due 2029 (the “Notes”).”

Ryman Hospitality Properties, Inc. amended Incremental Tranche B Term Loan Agreement with Wells Fargo Bank, National Association, as Administrative Agent (effective 2024-04-12).

“On April 12, 2024, Ryman Hospitality Properties, Inc. (the “Company”), entered into an Incremental Tranche B Term Loan Agreement (the “Incremental Agreement”), which supplements that certain Credit Agreement dated as of May 18, 2023 (the “Credit Agreement”), by and among RHP Hotel Properties, LP, as the borrower thereunder, (in such capacity, the “Borrower”), the Company and certain subsidiaries of the Company, as guarantors, several lenders named therein (the “Lenders”), Wells Fargo Bank, National Association, as Administrative Agent (in such capacity, the “Administrative Agent”), the joint lead arrangers and the various other parties thereto.”

RIGEL PHARMACEUTICALS INC amended Amendment No. 4 to Credit and Security Agreement with MidCap Financial Trust valued at Extended maturity to September 1, 2027; interest-only period to October 1, 2025; interest rate SOFR+ (effective 2024-04-11).

“On April 11, 2024, Rigel Pharmaceuticals, Inc. (“ Rigel ”) entered into Amendment No. 4 (the “ Amendment ”) to that certain Credit and Security Agreement, dated as of September 27, 2019 (as further amended, supplemented or otherwise modified from time to time prior to the Amendment, the “ Existing Credit Agreement ,” and as amended by the Amendment, the “ Amended Credit Agreement ”) with Midcap Financial Trust (“ MidCap ”), as administrative agent, and the lenders party thereto (“ Lenders ”), pursuant to which MidCap and the Lenders agreed to amend the Existing Credit Agreement to, among other things, (i) extend the maturity date for the term loans to September 1, 2027 (the “ Maturity Date ”), (ii) extend the interest only period for the term loans to October 1, 2025, (iii) reset the prepayment fee applicable to the term loans, (iv) increase the exit fee payable on the term loans, (v) revise the interest rate payable on the term loans, and (vi) update certain financial covenants in con”

SOLESENCE, INC. entered into Binding Memorandum of Understanding with BASF Corporation valued at Binding Memorandum of Understanding regarding Nanophase developing modified zinc oxide product for B (effective 2024-04-10).

“on April 10, 2024, Nanophase Technologies Corporation (“Nanophase”) and BASF Corporation (“BASF”) entered into an Amendment No. 5 (the “Amendment”) to Zinc Oxide Supply Agreement, dated as of September 16, 1999, as amended (the “Agreement”), and a Binding Memorandum of Understanding regarding Nanophase using its commercially reasonable efforts to develop a modified zinc oxide product for BASF’s exclusive purchase under the Agreement (the “Modified Product MOU”).”

SOLESENCE, INC. amended Amendment No. 5 to Zinc Oxide Supply Agreement with BASF Corporation valued at Amendment No. 5 to Zinc Oxide Supply Agreement, dated as of September 16, 1999, as amended, and Bind (effective 2024-04-10).

“on April 10, 2024, Nanophase Technologies Corporation (“Nanophase”) and BASF Corporation (“BASF”) entered into an Amendment No. 5 (the “Amendment”) to Zinc Oxide Supply Agreement, dated as of September 16, 1999, as amended (the “Agreement”), and a Binding Memorandum of Understanding regarding Nanophase using its commercially reasonable efforts to develop a modified zinc oxide product for BASF’s exclusive purchase under the Agreement (the “Modified Product MOU”).”

VERTEX PHARMACEUTICALS INC / MA entered into Agreement and Plan of Merger with Alpine Immune Sciences, Inc. valued at $65.00 per share (effective 2024-04-10).

“On April 10, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Alpine Immune Sciences, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”).”

Healthier Choices Management Corp. amended Securities Purchase Agreement with Purchasers (effective 2024-04-08).

“On April 8, 2024, HCWC and the Purchasers entered into the Amendment in order to issue the Bridge Warrants in lieu of the Bridge Shares”

Healthier Choices Management Corp. entered into Securities Purchase Agreement with institutional investors valued at $1.889 million (effective 2024-01-18).

“Healthy Choice Wellness Corp. (“HCWC”), a subsidiary of the Issuer, entered into a Securities Purchase Agreement (the “SPA”) with institutional investors (the “Purchasers”) pursuant to which HCWC agreed to issue (1) unsecured promissory notes with an aggregate principal amount of $1.889 million”

VBI Vaccines Inc/BC entered into Securities Purchase Agreement with institutional investors valued at $0.88 per Share (effective 2024-04-09).

“VBI Vaccines Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with institutional investors, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Offering”), (i) 2,272,728 common shares (the “Shares”) of the Company, no par value per share (the “Common Shares”), and (ii) warrants (the “Common Warrants”) to purchase up to 2,272,728 Common Shares, at a purchase price of $0.88 per Share and associated Common Warrant.”

LOGILITY SUPPLY CHAIN SOLUTIONS, INC entered into Reclassification Agreement with James C. Edenfield (effective 2024-04-10).

“the Company entered into a Reclassification Agreement, dated April 10, 2024 (the “Reclassification Agreement”), with James C. Edenfield”

HPS Corporate Capital Solutions Fund entered into Senior Secured Revolving Credit Agreement with JPMorgan Chase Bank, N.A. valued at $500,000,000 initial principal, up to $1,000,000,000 total facility (effective 2024-04-08).

“On April 8, 2024, HPS Corporate Capital Solutions Fund (the “ Fund ”), as borrower, entered into a senior secured revolving credit facility (the “ Facility ”) pursuant to a Senior Secured Revolving Credit Agreement (the “ Agreement ”), with JPMorgan Chase Bank, N.A., as administrative agent and as collateral agent, the lenders party thereto (the “ Lenders ”), and JPMorgan Chase Bank, N.A. and Sumitomo Mitsui Banking Corporation, as joint bookrunners and joint lead arrangers.”

Ispire Technology Inc. entered into JV Agreement with Chemular Inc., Touch Point Worldwide, Inc. d/b/a Berify, and Ike Tech LLC valued at $1 million in cash (effective 2024-04-05).

“ontribution, subscription, and joint venture agreement (the “JV Agreement”) with Chemular Inc., a Michigan corporation (“Chemular”), Touch Point Worldwide, Inc.”

RXO, Inc. amended Amendment No. 2 to the Revolving Credit Agreement with Citibank, N.A. valued at Increases consolidated leverage ratio financial covenant to 4.25:1.00 for Q2 and Q3 2024, 4.00:1.00 (effective 2024-04-11).

“On April 11, 2024, RXO, Inc. (the “Company”) entered into Amendment No. 2 to the Revolving Credit Agreement (the “Amendment”), with the lenders party thereto and Citibank, N.A., as administrative agent, which Amendment amends the Revolving Credit Agreement, dated as of October 18, 2022, among the Company, the guarantors from time to time party thereto, the lenders and other parties from time to time party thereto and Citibank, N.A., as administrative agent (the “Revolver”).”

MANGOCEUTICALS, INC. entered into Securities Purchase Agreement with an institutional accredited investor valued at $1,650,000 (effective 2024-04-05).

“Effective on April 5, 2024 (the " Initial Closing Date "), Mangoceuticals, Inc., a Texas corporation (the " Company ", " we " and " us "), agreed to definitive terms on a Securities Purchase Agreement dated April 4, 2024 (the " SPA "), with an institutional accredited investor (the " Purchaser "), pursuant to which the Company agreed to sell to the Purchaser, and the Purchaser agreed to purchase from the Company, 1,500 shares of Series B Convertible Preferred Stock (" Series B Preferred Stock ") of the Company for $1,650,000, and warrants”

Pegasus Digital Mobility Acquisition Corp. entered into Non-Redemption and Investment Agreements with certain third parties valued at approximately USD 20 million (effective 2024-04-11).

“On April 11, 2024, Pegasus Digital Mobility Acquisition Corp. (the “Company”), Pegasus Digital Mobility Sponsor LLC (the “Sponsor”), and Pegasus TopCo B.V. ("TopCo") entered into non-redemption and investment agreements (the “Non-Redemption and Investment Agreements”) with certain third parties”

Blue Ocean Acquisition Corp entered into Sponsor Promissory Note with Blue Ocean Sponsor LLC valued at $750,000 (effective 2024-04-05).

“On April 5, 2024, Blue Ocean Acquisition Corp (the “ Company ”) issued an unsecured promissory note to Blue Ocean Sponsor LLC (“ Payee ”) with a principal amount equal to $750,000 (the “ Sponsor Promissory Note ”).”

Century Therapeutics, Inc. entered into Agreement and Plan of Merger with Clade Therapeutics, Inc. valued at aggregate upfront consideration was approximately $35 million (effective 2024-04-11).

“On April 11, 2024, the Company, Clarent Intermediate Sub, Inc. (“Intermediate Sub”), a wholly owned subsidiary of Company, and Clarent Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of Intermediate Sub, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Clade Therapeutics, Inc. (“Clade”) and Fortis Advisors LLC, solely in its capacity as Securityholders’ Agent.”

Century Therapeutics, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at aggregate gross proceeds of approximately $60 million (effective 2024-04-11).

“On April 11, 2024, Century Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 15,873,011 shares of the Company’s common stock, par value $0.0001 per share (the “Private Placement Shares”), at a price of $3.78 per share (the “Private Placement”).”

NKGen Biotech, Inc. amended Amendment with East West Bank (effective 2024-04-05).

“On April 5, 2024, the Borrower entered into an amendment (the " Amendment ") to the EWB Credit Agreement to (i) eliminate the requirement of Borrower to maintain a minimum cash balance of $15 million with East West Bank, (ii) extend the maturity date to September 18, 2024, and (iii) require the Borrower to maintain its depository account(s) at East West Bank.”

NKGen Biotech, Inc. entered into Registration Rights Agreement with BDW Investments LLC (effective 2024-04-05).

“In connection with the Loan Agreement, Note and Warrant, the Company entered into a registration rights agreement (" Registration Rights Agreement "), dated April 5, 2024, with the Lender.”

NKGen Biotech, Inc. entered into Warrant with BDW Investments LLC (effective 2024-04-05).

“Pursuant to the Loan Agreement, the Company also issued a Common Stock Purchase Warrant (the " Warrant ") to the Lender to purchase up to 1,000,000 shares of Common Stock (the " Warrant Shares ") at an exercise price of $2.00 per share (subject to adjustments and limitations as described in the Warrant) for a period of five years from the issue date.”

NKGen Biotech, Inc. entered into Note with BDW Investments LLC valued at $5 million (effective 2024-04-05).

“On April 5, 2024, pursuant to the Loan Agreement and evidencing the Term Loans as described above, the Company issued to Lender a secured convertible promissory note (the " Note ") in the principal amount of up to $5 million and bearing interest at the Applicable Rate.”

NKGen Biotech, Inc. entered into Loan Agreement with BDW Investments LLC valued at $5 million (effective 2024-04-05).

“On April 5, 2024, NKGen Biotech, Inc. (the " Company ") entered into an equity and business loan agreement (the " Loan Agreement "), by and among the Company, NKGen Operating Biotech, Inc. (the " Borrower ") and BDW Investments LLC (the " Lender ").”

Velo3D, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at 7.0% of the aggregate purchase price (effective 2024-04-10).

“on April 10, 2023, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”).”

Velo3D, Inc. entered into Purchase Agreements with certain investors valued at approximately $12 million (effective 2024-04-10).

“On April 10, 2024, Velo3D, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain investors (collectively, the “Purchasers”).”

HPS Corporate Lending Fund terminated Managing Dealer Agreement dated August 3, 2021 with Emerson Equity LLC with Emerson Equity LLC valued at Termination effective as of April 11, 2024. (effective 2024-04-11).

“the Fund provided notice for the termination of the managing dealer agreement dated as of August 3, 2021 by and between the Fund and Emerson Equity LLC, which termination shall be effective as of April 11, 2024.”

Climb Bio, Inc. entered into Securities Purchase Agreement with several accredited institutional investors valued at 31,238,282 shares of the Company’s common stock ... at a price of $3.84 per PIPE Share (effective 2024-04-10).

“On April 10, 2024, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with several accredited institutional investors (the “PIPE Investors”), pursuant to which the Company agreed to issue and sell to the PIPE Investors in a private placement an aggregate of 31,238,282 shares of the Company’s common stock (the “PIPE Shares”), at a price of $3.84 per PIPE Share (the “Private Placement”).”

Climb Bio, Inc. entered into Agreement and Plan of Merger and Reorganization with Tenet Medicines, Inc. (effective 2024-04-10).

“On April 10, 2024, Eliem Therapeutics, Inc. (the “Company”) entered into an Agreement and Plan of Merger and Reorganization (the “Acquisition Agreement”) by and among the Company, Tango Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Transitory Subsidiary”), Tenet Medicines, Inc., a Delaware corporation (“Tenet”), and, solely in his capacity as company equityholder representative, Stephen Thomas.”

STERIS plc entered into Equity Purchase Agreement with HuFriedy Group Holding LLC valued at $787.5 million in cash, subject to customary adjustments, and up to $12.5 million in contingent paym (effective 2024-04-10).

“On April 10, 2024, STERIS Corporation (“Seller”), a wholly owned subsidiary of STERIS plc (“STERIS”), and certain affiliates, entered into an Equity Purchase Agreement (the “Purchase Agreement”) with HuFriedy Group Holding LLC (the “Purchaser”), an affiliate of Peak Rock Capital LLC.”

Canoo Inc. entered into Purchase Agreement with certain special purpose vehicles managed by entities affiliated with Mr. Tony Aquila valued at $10,000,000 (effective 2024-04-09).

“On April 9, 2024 (the “Agreement Date”), Canoo Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain special purpose vehicles managed by entities affiliated with Mr. Tony Aquila, the Company’s Chief Executive Officer and Executive Chair (collectively, the “Purchasers”), in connection with the issuance, sale and delivery by the Company of an aggregate of 10,000 of shares (the “Preferred Shares”) of the Company’s Series C Cumulative Perpetual Redeemable Preferred Stock, par value $0.0001 per share (the “Preferred Stock”), which is convertible into shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and pursuant to which the Company issued warrants (the “Warrants”) to purchase in the aggregate 4,473,272 shares of Common Stock, for a total aggregate purchase price of $10,000,000.”

Monroe Capital Income Plus Corp amended Credit Agreement with KeyBank National Association valued at $119.5 million of aggregate commitments to $194.5 million of aggregate commitments (effective 2024-04-09).

“On April 9, 2024, Monroe Capital Income Plus Corporation (the “Company”), increased the Facility Amount pursuant to the accordion feature of the Term Credit and Security Agreement, dated December 20, 2022 (as amended, the “Credit Agreement”), between MC Income Plus Financing SPV II LLC, a wholly-owned subsidiary of the Company as borrower (the “Borrower”), and the Company, as collateral manager, with KeyBank National Association, as administrative agent (the “Administrative Agent”) and lead arranger, the lenders from time to time party thereto, U.S. Bank Trust Company, National Association, as collateral agent and collateral administrator, and U.S. Bank National Association, as document custodian (the “Credit Facility”).”

Longeveron Inc. amended Warrant Amendment Agreement with a holder (the “Holder”) of existing warrants (effective 2024-04-08).

“the Company also entered into an agreement (the “Warrant Amendment Agreement”) with a holder (the “Holder”) of existing warrants to purchase shares of the Company’s Common Stock to, in consideration for the Holder’s participation in the Offering and purchase of securities in the Offering, and contingent upon the closing of the Offering and the Holder’s participation in the Offering, amend the Holder’s existing warrants to purchase up to (a) 242,425 shares of common stock at an exercise price of $16.50 per share, issued on October 13, 2023 and expiring on April 13, 2029 (the “Series A Warrants”) and (b) 242,425 shares of common stock at an exercise price of $16.50 per share, issued on October 13, 2023 and expiring on April 14, 2025 (the “Series B Warrants” and together with the Series A Warrants, the “Existing Warrants”) to (i) reduce the Exercise Price (as defined in the Existing Warrants) of the Existing Warrants to $2.35 per share and (ii) amend the expiration date of the Series A Wa”

Longeveron Inc. entered into engagement letter with H.C. Wainwright & Co., LLC valued at 7.0% of the aggregate gross proceeds (effective 2024-03-01).

“As compensation to H.C. Wainwright & Co., LLC (the “Placement Agent”), pursuant to an engagement letter, dated as of March 1, 2024, as amended on April 3, 2024, and April 9, 2024, by and between the Company and the Placement Agent, pursuant to which the Placement Agent agreed to act as the exclusive placement agent in connection with the Offering, the Company paid the Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds raised in the Offering, plus a management fee equal to 1.0% of the aggregate gross proceeds raised in the Offering and certain expenses incurred in connection with the Offering.”

Longeveron Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $5.20 million (effective 2024-04-08).

“Certain institutional investors purchasing securities as part of the Offering entered into a securities purchase agreement with the Company (the “Purchase Agreement”), dated as of April 8, 2024.”

ARVINAS, INC. entered into License Agreement with Novartis Pharma AG valued at $150.0 million upfront, up to $1.01 billion in milestones (effective 2024-04-10).

“On April 10, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), entered into a transaction (the “Transaction”), including both a license agreement (the “License Agreement”) and an asset purchase agreement (the “Asset Agreement”), with Novartis Pharma AG (“Novartis”).”

Insight Molecular Diagnostics Inc. entered into Collaboration Agreement with Bio-Rad Laboratories, Inc. (effective 2024-04-05).

“On April 5, 2024, Oncocyte Corporation (the “Company”) entered into a Collaboration Agreement with Bio-Rad Laboratories, Inc. (“Bio-Rad”) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents (the “Collaboration Agreement”).”

FTAI Aviation Ltd. terminated 2025 Notes Indenture for 6.50% Senior Notes due 2025 with U.S. Bank Trust Company, National Association valued at Redemption of $650.0 million aggregate principal amount of 6.50% Senior Notes due 2025, deposit of $ (effective 2024-04-02).

“On April 2, 2024, under the indenture, dated as of September 18, 2018, between the Issuer and the Trustee (as supplemented from time to time, the “2025 Notes Indenture”), the Issuer issued a conditional notice of redemption for any and all of the Issuer’s $650.0 million outstanding aggregate principal amount of its 2025 Notes, less the aggregate principal amount of 2025 Notes validly tendered and accepted in the Issuer’s concurrent Tender Offer.”